Correlation Engine 2.0
Clear Search sequence regions


  • adult (2)
  • angiomyolipoma (5)
  • blood (1)
  • cases (1)
  • everolimus (9)
  • female (1)
  • humans (1)
  • patients (5)
  • renal angiomyolipoma (1)
  • serum (1)
  • treatment effects (1)
  • weight (4)
  • Sizes of these terms reflect their relevance to your search.

    The aim of this study was to evaluate the safety and efficacy of low-dose everolimus treatment in patients with tuberous sclerosis complex (TSC)-associated angiomyolipoma (AML) with renal dysfunction or low body weight. We investigated a total of 50 adult patients underwent everolimus treatment for AML associated with TSC. For patients with renal dysfunction (serum creatinine level ≥ 1.5 mg/dl) or low body weight (body weight < 35 kg), 5 mg of everolimus was administered daily (low-dose group). For patients without renal dysfunction or low body weight, 10 mg of everolimus was administered daily (conventional-dose group). The treatment effects and adverse events were compared between the two groups. There were 20 patients in the low-dose group, and 30 in the conventional-dose group. The average reduction rate of the AML volume in the low-dose group was 52%, whereas it was 60% in the conventional-dose group. No significant differences were found in the average reduction rate between the groups (P = 0.24). The average blood everolimus trough levels were 7.7 ± 3.1 ng/mL in the low-dose group and 12.2 ± 5.7 ng/mL in the conventional-dose group. The level was significantly higher in the conventional-dose group than in the low-dose group (P = 0.004). The incidences of stomatitis and irregular menstruation were significantly lower in the low-dose group than in the conventional-dose group (P = 0.009, P = 0.045, respectively). The present study demonstrates that low-dose everolimus treatment is safe and effective for TSC-associated AML. This treatment was well tolerated and adverse events were mild in all cases.

    Citation

    Takashi Hatano, Katsuhisa Endo, Mayumi Tamari. Efficacy and safety of low-dose everolimus treatment for renal angiomyolipoma associated with tuberous sclerosis complex. International journal of clinical oncology. 2021 Jan;26(1):163-168

    Expand section icon Mesh Tags

    Expand section icon Substances


    PMID: 32990779

    View Full Text